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The liver transplantation program of the University Medical Center Groningen in the 
Netherlands was started in 1979, making it one of the first programs worldwide. During 
the past 36 years, a total of 1478 liver transplantations have been performed, 459 of 
which were in children. One of the first patients transplanted in 1979 is still alive and is 
one of the longest surviving patients after liver transplantation worldwide. During the 
last decade, an increasing number of donation after circulatory death (DCD) donor livers 
have been accepted for transplantation. Over 30% of the livers transplanted in 
Groningen come from DCD donors. These livers have an increased risk of developing 
non-anastomotic biliary strictures (NAS). One of the main research topics in Groningen 
has been the pathogenesis and prevention of NAS. In an attempt to reduce the incidence 
of NAS after liver transplantation, machine perfusion technology has been developed as 
an alternative to the traditional method of static cold storage. Researchers of the 
Groningen liver transplant team were the first in the world to report a method of ex situ 
normothermic machine perfusion of human donor livers. The efficacy and safety of 
various types of machine perfusion are currently studied in both animal models and 
clinical trials. A second line of research in Groningen focuses on alterations in the blood 
coagulation system in patients with liver disease and undergoing liver transplantation. 
Groningen researchers were the first to describe a ‘rebalanced state’ of the coagulation 
system in patients with liver disease, making them prone to both bleeding and thrombo-
embolic complications. Clinicians and researchers at the Groningen liver transplant 
program will continue to collaborate with a shared focus and the aim to provide 
innovation and the highest level of care to patients with end stage liver disease.  
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A brief history of liver transplantation  
 
Pioneers of the field  
 
For approximately 50 years it was thought that the first liver transplantation was 
reported in 1955 by Welch and colleagues, who performed a series of auxiliary liver 
transplants in dogs (1). Recently, however, the 1952 work of Vittorio Staudacher came 
to light (2). He describes an orthotopic liver transplantation (OLT) method performed in 
dogs, similar to the procedure used in humans today (3). In 1958, surgeons from the 
Northwestern University in Chicago and Brigham Hospital in Boston conducted liver 
transplantation experiments in dogs and found that transplantation success hinges on 
several prerequisites (4,5). First, prevention of ischemic injury was indispensable (4). 
This was achieved through hypothermic preservation, in this case by flushing the graft 
with chilled Ringer’s lactate. Second, congestive damage to the recipients’ splanchnic and 
systemic venous vasculature was avoided using a venous bypass, yielding improved 
survival (4,6). During these early stages, developments in kidney transplantation 
provided a stimulating example to the emerging field of liver transplantation (7). Prior 
experience with renal transplantation facilitated the use of immunosuppressive agents. 
For example, treatment with azathioprine before and after liver transplantation together 
with high doses of prednisone administered at the onset of rejection, increased the 
overall success of liver transplantation (8). Over the course of 30 years, these 
developments led to the world-wide implementation of liver transplantation. 
 
The first human liver transplantation 
 
The first human liver transplantation was performed by Thomas Starzl at the University 
of Colorado in 1963. The operation involving a three-year-old boy, was complicated by 
an unforeseen degree of adhesions, causing massive – and ultimately fatal –  
hemorrhage (9). Nevertheless, Starzl and his team performed three more 
transplantations that same year (9,10). All three cases were complicated by a pulmonary 
embolism shortly after surgery, which limited follow-up to a maximum of 22 days. It was 
presumed that antifibrinolytic therapy with ε-aminocaproic acid (EACA), together with 
the peri-operative administration of cryoprecipitate and blood transfusions resulted in 
venous thrombosis (9). In addition, the tubing used for the veno-venous bypass 
activates the coagulation system. By January 1964, three different centers across the 
world had performed 7 human liver transplantations, all with unsatisfactory results (6, 
10, 11), leading to a consensus that the procedure was too technically challenging 
(12,13). However, as the research focus shifted towards immunosuppression and organ 
preservation, the introduction of antilymphocyte globulin (ALG) as part of a so-called 
“triple drug cocktail” (together with azathioprine and prednisone), signified a turning 
point (14,15). After a series of successes with canine studies, attempts to perform 
human liver transplantation were resumed in the late sixties. During the summer of 
1967, Starzl performed the first successful human liver transplantation on an 18-month 
old girl in Denver, CO (16). This inspired several other centers across the world. Sir Roy 
Calne started a human liver transplantation program in Cambridge, UK in 1968 (17). By 
1969, Starzl's group in Denver and Calne's group in Cambridge had successfully 
performed a total of 25 liver transplants (18). Between 1972 and 1979, the university 
hospitals in Hannover (Germany), Paris (France), and Groningen (The Netherlands) 
started liver transplantation programs. Together, these academic hospitals laid the 
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Liver transplantation in Groningen 
The first liver transplantation in Groningen took place in 1979 and was performed by 
surgeons Ruud Krom and Gauke Kootstra, in collaboration with hepatologist Chris Gips. 
At that time, the survival rate after liver transplantation in other centers was 
approximately 30% (20,21). Euro-Collins’ solution was used as preservation solution 
(23). Immunosuppression consisted of prednisone and azathioprine. The surgical 
technique was performed as developed by Starzl and Calne , with the exception of the 
biliary anastomosis; Krom and colleagues applied an end-to-end 
choledochocholedochostomy using a T-shaped biliary stent, in preference to the 
cholecystojejunostomy with Roux-Y reconstruction as described by Starzl (9, 20, 21, 23, 
24). This innovation resulted in a significant reduction of biliary complications and is 
presently the preferred technique worldwide (25). Notably, the Groningen transplant 
team added selective bowel decontamination to the protocol, which was later adopted by 
other centers (19,26). Despite elaborate preparation, the first patient to receive a donor 
liver in Groningen succumbed due to massive intraoperative hemorrhage (24). Yet in the 
first cohort of 27 procedures, 1- and 2-year survival rates were 60%, and the reported 
quality of life was excellent (23). The recipient of the first successful liver transplantation 
performed in Groningen in 1979 is alive today and one of the longest surviving liver 
transplant recipients worldwide. Based in part on the favorable results reported by the 
Groningen team, the National Institutes of Health declared liver transplantation an 
established therapy for end-stage liver disease in 1983 (27).  
In the Netherlands, pediatric liver transplantations are only performed in Groningen. The 
first liver transplantation in a child was performed in 1982 (28). In the years to follow, 
the liver transplant program in Groningen was refined through scientific research. Since 
the start of the program, a total of 1478 liver transplantations have been performed 
throughl January 2016, 459 of which in children (Figure 1). From the year 2000 on, 1- 
and 5-year survival rates for adults and children increased to around 90% (Figure 2). 
These increases were due to improvements in patient selection, organ preservation, 
surgical technique, and the development of new immunosuppressive regimens (29).  
20
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Figure 1. Cumulative number of transplants performed between 1979 and 2015 in Groningen. In 
1979 a total of 4 adult liver transplantations were conducted. The first pediatric liver transplantation was 
performed in 1982. Around 1990, the number of transplantations in both adults and children started to 
increase due to increasing experience and good results. During the last 36 years, a total of 1019 adult liver 
transplantations and 459 pediatric liver transplantations have been performed.  
Figure 2. Actual 1-year patient survival rates in adult and pediatric liver transplant recipients 
transplanted in 2013 and 2014, in Groningen. 
Cumulative Number of Transplants
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Current practice  
 
Indication for transplantation  
 
The most common indications for adult liver transplantation in Groningen are primary 
sclerosing cholangitis (PSC), post-alcoholic and post-viral cirrhosis (Figure 3). The 
incidence of non-alcoholic steatohepatitis (NASH) is gradually increasing and this type of 
liver disease is expected to become one of the leading indications for liver 
transplantation in the Netherlands in the coming years. In children, a liver 
transplantation is most commonly performed in the setting of congenital disorders 
(cholestatic or metabolic), pediatric cancer (hepatoblastoma) or acute hepatic failure. In 
more than 50% of the cases, the leading indication for pediatric liver transplantation is 




Figure 3. Indications for adult liver transplantation in the time period 2000 - 2014. Primary sclerosing 
cholangitis, postviral cirrhosis and postalcoholic cirrhosis were the most common indications for 
transplantation. Abbreviations : PSC, primary sclerosing cholangitis; PBC,  primary biliary cholangitis; NASH,  
non-alcoholic steato-hepatitis.  
 
The Netherlands is one of the countries that belong to the Eurotransplant network for 
organ sharing. The allocation of donor livers is based on a patient-oriented system. Until 
December 2006, the Child-Pugh score was used to prioritize patients on the waiting list. 
Patients with equal Child-Pugh scores were sorted according to the time they had spent 
on the waiting list. To improve donor liver allocation, the model for end-stage liver 
disease (MELD) score was introduced in the Eurotransplant region in 2006, leading to an 
allocation process in which waiting time became less important and mortality on the 
waiting list decreased. 
















Protocols for immunosuppressive therapy in the Groningen liver transplant program have 
gradually changed during the past decades. While the original immunosuppressive 
protocol in the early 1980s was based on azathioprine and relatively high doses of 
prednisone, the current protocol is based on a calcineurin inhibitor and a rapid taper of 
prednisone. While cyclosporin was the only calcineurin inhibitor available between the 
mid-1980s and mid-1990s, it is currently almost completely replaced by tacrolimus. 
However, until a few years ago, cyclosporin was still considered the calcineurin inhibitor 
of choice in patients with an immune-mediated liver disease, such as PSC, primary 
biliary cholangitis (PBC), or autoimmune hepatitis. Induction therapy has almost 
universally been part of the immunosuppressive protocol in the Groningen liver 
transplant program during the past decades. In the 1980s and 1990s this consisted of 
cyclophosphamide, which was replaced by basiliximab around 1996. Currently, 
basiliximab is still being used as induction therapy in both adult and pediatric liver 
transplant recipients.  
Intraoperative hemorrhage 
For many years, bleeding complications were one of the most frequent causes of 
morbidity and mortality in liver transplant recipients. The mechanisms underlying this 
problem, as well as developing strategies to reduce intraoperative blood loss, have been 
the subject of extensive research in Groningen during the past decades. This has 
generated a large number of scientific publications and PhD theses. A few important 
milestones include the identification of hyperfibrinolysis as a critical cause of increased 
blood loss during liver transplantation, the beneficial effects of the antifibrinolytic drug 
aprotinin, and identification of the risk of thrombo-embolic complications in liver 
transplant recipients (30-40). Fundamental research on changes in the hemostatic 
system in patients with liver disease performed in Groningen has increased the 
understanding of coagulation abnormalities in patients with liver disease. Whereas the 
traditional dogma asserted that a diminished coagulation capacity (hypocoagulability) in 
patients with liver disease was the net result of liver disease-induced changes in 
hemostasis, it is currently widely accepted that the hemostatic system in these patients 
are in a so-called 'rebalanced' state, in which both bleeding and thrombotic 
complications are more likely to occur (41). For example, increased bleeding during liver 
transplantation is more frequently caused by increased portal venous pressure than by a 
hypocoagulable state (37). Based on evolving new insights such as these, perioperative 
blood transfusion requirements have been greatly reduced. Currently, around 25% of all 
adult first liver transplantations in Groningen are conducted without the need for blood 
transfusion (33,37). 
Shortage of suitable donor livers 
The increasing demand for liver transplantation has resulted in a world-wide donor organ 
shortage. Many efforts have been made to expand the donor pool, such as the 
acceptance of extended criteria donor (ECD) livers, split- and domino liver transplants, 
and the introduction of living donor liver transplantation.  
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Living donor liver transplantation 
The Groningen team started a living donor liver transplant program in 2004. Currently, 
living donor liver transplantations comprise up to 1/3 of all pediatric liver 
transplantations in Groningen, with 1- and 3- year patient survival rates of 96% and 
88%, respectively.  
Extended criteria donor livers 
In 1968 guidelines defining brain death were published, enabling standardized use of 
livers derived from brain-dead donors (42). The increasing success rate of liver 
transplantation, resulted in more indications for liver transplantation, a higher need for 
donor organs and, subsequently, a shortage. In the late 1990s, the shortage of suitable 
donor livers for transplantation resulted in a gradual widening of the acceptance criteria 
for donation. More frequently donor livers were accepted that carried an increased risk 
for early graft failure or disease transmission. These, so called 'extended criteria donor' 
(ECD) livers now comprise the majority of donor livers accepted for transplantation in 
Groningen. ECD livers include steatotic livers, livers donated after controlled circulatory 
death (DCD), and livers from elderly donors. The first attempts to use DCD livers were 
made in the 1980s (43-45). In the Netherlands, a national protocol for DCD was 
implemented in 2001 (46). Since then, the number of DCD liver transplants has 
gradually increased and now contributes to around 40% of all liver transplants 
performed. While the number of DCD liver transplants in the Netherlands is still rising, 
some other countries that belong to the Eurotransplant network (i.e. Germany) do not 
allow DCD donation (47). The first DCD liver transplant procedure in Groningen was 
performed in 2004. Whereas overall survival of DCD liver transplant recipients is 
comparable to that of DBD liver recipients, DCD transplants are associated with an 
increased rate of biliary complications (Figure 4).  
Figure 4. The cumulative incidence of  non-anastomotic strictures (NAS) after DBD and DCD liver 












Biliary complications occur in 10% to 40% of liver recipients, depending on the 
definitions used (48-50). Most common are anastomotic bile leakage (2-21%) and 
anastomotic or non-anastomotic (NAS) bile duct strictures (1-30%) (51). In DCD liver 
transplantation, NAS occur in up to 30% of cases, with 50% of these resulting in 
retransplantation or death. The majority of cases of NAS after DCD liver transplantation 
are observed within 6 months after transplantation. Due to the increasing number of 
DCD liver transplantations in our center, the pathogenesis and prevention of NAS has 
become an active area of research with the overall aim to reduce the high rate of biliary 
complications after this type of liver transplantation. Proposed mechanisms involved in 
the development of NAS include ischemia-related injury, immune-mediated injury, 
cytotoxic injury induced by hydrophobic bile salts, and impaired epithelial regeneration 
(48,52,53) (Table 1). The effect of post-transplant bile composition and the role of bile 
salt toxicity in the development of NAS was extensively studied by the Groningen group, 
both in experimental animal studies and clinical studies (54,55). It has been 
demonstrated that bile salts contribute to the development of biliary injury due to the 
cytotoxic effect on biliary epithelium and other cell types in the bile duct wall. In three 
independent clinical studies, including one collaborative study from Groningen and 
Boston (Massachusetts General Hospital) it was recently demonstrated that almost all 
human donor livers grafts have signs of severe biliary epithelial injury at the time of 
transplantation (53,56,57). This finding has changed our understanding of the 
pathogenesis of NAS (52). Although biliary epithelial cell loss is almost universally 
present in donor livers at the time of transplantation, only a minority (up to 15% in DBD 
liver transplantation and up to 30% in DCD liver transplantation) develop NAS. This 
finding suggests that insufficient biliary epithelial regeneration rather than the initial 
amount of epithelial injury is the mechanism underlying the development of NAS. This 
hypothesis was confirmed by the identification of histological injury of the peribiliary 
glands and the peribiliary vascular plexus as independent risk factors for the 
development of NAS after liver transplantation (52,53,58). The peribiliary glands have 
been identified as a niche of biliary progenitors cells, which are mobilized after severe 
biliary epithelial injury  (58,59). These findings have made the peribiliary vascular plexus 
and the peribiliary glands important new targets in our research focusing on the 
prevention of NAS after liver 
transplantation. A much promising method that may enable better preservation of the 
bile ducts of liver grafts is machine perfusion. 
2
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Table 1. Four main mechanisms underlying the development of non-
anastomotic biliary strictures (NAS) after liver transplantation. 
Machine perfusion 
First described by Charles Lindbergh and Alexis Carrel  in 1935, machine perfusion is an 
organ preservation technique that involves the ex situ perfusion of donor organs using a 
machine (60). During machine perfusion, an organ is artificially circulated with (a) blood 
(substitute) provided through the afferent vessel(s). Machine perfusion can be 
performed in a myriad of ways. Perfusion solution, temperature of the perfusion solution, 
oxygenation of the perfusion solution, etcetera are all variables in machine perfusion 
that are being investigated by different research groups including Groningen. The 
optimal execution of machine perfusion remains to be established and depends on the 
indication for the perfusion.  
A Promising Technique 
In general, machine perfusion can serve three different goals: a) improve organ 
preservation, b) allow functional assessment of a donor organ prior to transplantation, 
and c) allow longer preservation of donor organs. Due to the increasing use of sub-
optimal quality donor organs, such as ECD livers, machine perfusion is currently 
receiving much attention. It has the potential to provide better preservation of ECD liver 
grafts, which may contribute to a reduction of graft-related complications after 
transplantation and may help expand the donor liver pool. Currently, the most widely 
studied methods of liver machine preservation include hypothermic (4-12 oC) and 
normothermic (37 oC) machine perfusion (61). 
Oxygenated hypothermic machine perfusion (HMP) offers the ability to ‘resuscitate’ DCD 
livers. In several animal and human studies oxygenated HMP has been shown to 
increase ATP content in DCD livers, while hepatic ATP content is virtually nil in DCD livers 
preserved by traditional  static cold storage (SCS) only (62,63). Due to a sustained ATP 
production, oxygenated HMP reduces ischemia-reperfusion injury and consequently bile 
Ischemia-related injury caused by: 
- Warm and cold ischemia associated with organ preservation
- Warm ischemia in donation after cardiac death donors
- Inadequate preservation of the peribiliary capillary plexus
Immune-mediated injury due to: 
- ABO-incompatible transplantation
- CMV-infection
- Female organs in male recipients
- Chemokine receptor CCR5-∆32 polymorphism
Cytotoxic effect of hydrophobic bile salts caused by: 
- Inadequate flush out of bile from the bile ducts at organ retrieval
- High biliary bile salt/ phospholipid ratio after transplantation
- Impaired cholehepatic shunt with intracellular accumulation of bile salts in
cholangiocytes
- Impairment of the protective HCO3- umbrella at the canalicular membrane of
cholangiocytes
Impaired biliary epithelial cell regeneration due to: 
- Insufficient blood supply to the peribiliary glands
26
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duct injury. After a series of experimental animal studies, the technolgy of oxygenated 
HMP (using a combination of arterial and portal perfusion) was recently tested in a 
human study in DCD liver transplantation. The results of this first clinical study have 
shown an excellent outcome with 100% graft and patient survival rates after a complete 
follow up of one year in all 10 patients included (R. van Rijn, R.J. Porte, et al. 
unpublished results). These favorable results have led to the initiation of a randomized 
controlled multicenter trial comparing oxygenated HMP with traditional SCS in DCD liver 
transplantation. The primary outcome parameter in the trial will be the incidence of NAS 
at 6 months after transplantation (ClinalTrial.gov identifier NCT02584283) 
Normothermic machine perfusion (NMP) is performed at 37 °C, resulting in metabolically 
active livers, offering the ability to assess donor liver function and viability ex situ. By 
assessing viability of ‘sub-optimal' quality livers that would otherwise have been 
discarded, more livers could be potentially identified as "transplantable". The first study 
demonstrating the feasibility of NMP of human donor livers was published by researchers 
from Groningen (64). Current evidence indicates that bile production and a decrease in 
lactate concentration in the perfusion fluid during NMP are important criteria that can be 
used to indicate well-functioning and potentially transplantable livers (65). The device 
that was developed by Groningen-based researchers to enable machine perfusion of 
human donor livers is now commercially available (www.organ-assist.nl) and allows 
perfusion at variable temperatures in a range of 10 to 37 oC (Figure 5). Researchers at 
the Groningen Transplant Center have not only been pioneering in the field of liver 
machine perfusion, but also in the fields of kidney and lung machine perfusion. This has 
led to the clinical introduction of machine perfusion technologies in all three types of 
organ transplantation. To facilitate the clinical application of machine preservation of 
donor livers, kidneys and lungs, a novel organ perfusion room has been developed. This 
dedicated facility for donor organ perfusion has been called the Organ Preservation & 
Resuscitation (OPR) unit and allows simultaneous perfusion of a pair of donor lungs, a 
liver and two kidneys (Figure 6). 
Future Research 
Ongoing research at the University of Groningen focuses on different approaches to 
improve our machine perfusion protocols, such as novel perfusion fluids with enhanced 
oxygen binding capabilities and dynamic temperature machine perfusion. More 
fundamental work focuses on the precise nature of NAS after transplantation, and how to 
counter the underlying mechanisms that cause these complications, including insufficient 
biliary regeneration from the peribiliary glands.  
Both fundamental and applied research findings will be required to improve the current 
practice of ECD and DCD liver transplantation. It is our view that ultimately, an organ 
will undergo several personalized stages of machine perfusion, subdivided into a primary 
stabilization phase, a viability testing phase, and a treatment phase. Hypothetically, the 
organ will first be stabilized with oxygenated HMP, minimizing any ongoing effects of 
ischemia and replenishing energy stores. Consequently, viability testing can be 
performed using NMP, which should determine the subsequent treatment regimen 
depending on the organ’s metabolic demands. As technology advances, machine 
perfusion systems will become increasingly dynamic, so that in the end, each organ will 
receive a tailor-made machine perfusion treatment.  
2
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Figure 5. Photo of the Liver Assist, a perfusion device for preservation of human donor liver developed by 
researchers in Groningen (Organ Assist, Groningen, the Netherlands). The Liver Assist is a pressure-controlled 
system that allows perfusion of a donor liver via both the portal vein and hepatic artery. The temperature 









Figure 6. Photo of the Organ Perfusion & Resuscitation (OPR) unit at the University Medical Center Groningen, 
the Netherlands. The OPR unit is a central facility within the operation center that allows simultaneous machine 
perfusion of a donor liver, a pair of donor lungs and two donor kidneys. 
2
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